Delaying the second dose of the mRNA coronavirus vaccines in younger people may lead to fewer deaths, but only if certain conditions are met, a predictive modelling study suggests.

The findings add to the current pandemic debate over whether to extend the gap between vaccine doses to give as many people as possible some protection, or to stick with the dosing intervals designated in clinical trials.